Search 

Acon Pharmaceuticals Inc. (Acon Pharma) is a specialty pharmaceutical company and focuses on BLA, ANDA, and 505(b)(2) NDA drug product development with its captive drug delivery system technology platforms. Acon Pharma provides service to its partners and customers to accelerate their IND and NDA product development by out-licencing its captive drug delivery platforms, pre-formulation, formulation, process development, and manufacturing of different types of dosage forms and drug delivery products. Our expertise covers drug development and delivery of poorly soluble small molecule drugs, siRNA, oligonucleotides, peptides, protein, and plasmid DNA. Our formulation technology platforms include nanoparticles, microspheres / microparticles, nanocrystals, liposome, implant, long-acting injectable, oral fast dissolving film (ODF), transdermal patches, resinate / polistirex suspension, nasal spray, topical cream, gel, ointment, nanoemulsion, microemulsion, self-emulsifying system, tablets, capsules, inhalers, controlled release, modified release, and delayed release.

Aequor discovered a new genus and several new species of marine microbes that produce “green,” non-toxic chemicals that target Gram-negative and Gram-positive bacteria and fungi, and uniquely remove biofilm in minutes and prevent biofilm formation for long periods of time. They kill the antimicrobial resistant (AMR) bacteria and fungi alone and as "potentiators" of very low doses (sub-MIC) of otherwise ineffective antibiotics, including Penicillin, to kill the AMR "Superbug" pathogens.
Biofilm is the first resistance response of microorganisms to protect themselves against environmental stresses and is associated with most infections and diseases. Removal of biofilm by surface scraping, UV, heat, biocides and antibiotics, etc. signal to the underlying microorganisms when and how fast to build a thicker biofilm shield.
The U.S. Centers for Disease Control (CDC) associate biofilm with 90% of hospital-acquired infections, such as those caused by contamination on indwelling medical devices, ventilators, and water and air systems. The CDC recently reported that 20% of U.S. COVID deaths were due to these secondary infections. Additional life-threatening infections are increasingly traced to biofilm in air and water systems in institutional and commercial buildings and homes. For example, Legionnaire’s Disease, which claimed 17 lives, was traced to biofilm in a hotel’s air conditioners that became aerosolized and inhaled. It is no coincidence that every pathogen on the CDC and WHO lists of urgent threats, pandemic threats, and bioterrorist threats is a biofilm-former. Every drug-resistant “Superbug” strain is a biofilm-former and is considered incurable. Additionally, several microbial species are captures in the same biofilm, increasing the incidence of horizontal gene transfer (Li et al., 2001; Angles et al., 1993; Dunny et al., 1995) and spawning the emergence of new antimicrobial-resistant (AMR) strains.
There are few remedies for biofilm. Physical removal (sterilization, scraping, UV) works for a short-term (e.g., biofilm was recorded on a titanium plate within 30 seconds of sterilization). Biocides (antiseptics, disinfectants, antimicrobials, and antibiotics) are designed to kill free-floating (planktonic), actively growing microorganisms, and the dose of needed to disrupt a biofilm is approximately 1000x the concentrations that are effective against planktonic bacteria (Raffa et al., 2003), which is a dose that is lethal to humans. The overuse of biocides and antibiotics has contributed to the emergence of the AMR Superbugs – and left a cumulative and persistent environmental footprint. Natural antimicrobials, such as silver and other metals, are expensive and eventually trigger the formation of thicker biofilm, resulting in the loss of efficacy over time.

Welcome to Allevetix Medical, a global leader in innovative medical technology focusing on treating metabolic diseases such as Type II Diabetes, Obesity, and NASH (Nonalcoholic steatohepatitis).

Allevetix team had developed the NobiX System. It is a non-surgical, fully-reversible, and natural treatment designed to mimic gastric bypass surgery's effects without any need for cuts, ablations, or permanent changes to the patient anatomy. It consists of a safe and non-invasive implant that prevents food contact with a section of the small intestine linked to hormone abnormality in metabolic diseases.
In a matter of months, the NobiX can naturally reduce body weight by 20% and lower HbA1C levels. The effects of the Nobix System begin immediately with patients feeling more energetic and less prone to symptoms of metabolic disease.

The NobiX System allows patients to recover naturally from metabolic diseases by promoting healing and balance in the duodenum through the avoidance of contact and metabolic reactions in this intestinal tract section. The NobiX can be removed and replaced anytime during the patient’s recovery. It is designed to assist patients with balancing metabolic disorders without any necessary changes to their lifestyle.

Alykomed Global Solutions LLC (AGSL), based in New York, is a respected and established provider of strategic personalized corporate solutions to the Biopharma industry. Our clients embody a wide range of companies, from innovative startups to larger established, public companies. Our projects include global business development, financial, investment, and capital support, and scientific based endeavors, among others. We are committed to our clients’ long term success, optimized growth strategies, and profitability potential.

We proudly apply our deep scientific knowledge, and combine this with our strong corporate and business development experience and an extensive scientific/business network. Our established and trusted financial investment banking service/registered broker partner, provides our clients with targeted capital and financial solutions and extensive access to institutional and retail investors. These capital services cover a wide range of investment opportunities and offerings, including, but not limited to IPOs and securities offerings, private placements, mergers and acquisition, bank and debt financing etc.

We also undertake strategic growth initiatives through global business development, researching scientific and drug development platforms, assisting with internal valuations, or assistance with other projects- we offer knowledge, experience, leadership, global awareness, and creativity. We work with a global network of professionals, having done business in North America, UK/Europe, and Asia, especially within the United States, Japan, South Korea, and China.

Aphios®, which means “virus-free” in Greek, is an emerging growth biotechnology company developing green enabling technology platforms for improving drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety in an environmentally-sustainable manner, and enhanced therapeutics for the treatment of infectious diseases, CNS disorders, cancers and supportive care.

Our lead product is Zindol® which has successfully completed a Phase 2/3 clinical trial as an adjuvant to conventional 5-HT3 anti-emetics in cancer patients undergoing chemotherapy. Other clinical products under development are APH-0812 for HIV latency and APH-1104 for Alzheimer’s disease. We have several preclinical leads in development for prostate, breast and pancreatic cancer, cancer pain and infectious diseases.

Our lead platform is CFI™ for the manufacture of virus-free biologics such as convalescent COVID-19 plasma, human plasma proteins and monoclonal antibodies as well as viral vaccines against influenza. Our drug discover discovery platform is being harnessed to develop antiviral therapeutics against the novel coronavirus and our nanotechnology platforms are being used to improve the delivery of HIV latency and Alzheimer’s disease therapeutics.

We are raising capital to conduct pivotal Phase 3 clinical trials of Zindol® for CINV to complete clinical development of Zindol and file an NDA with the FDA. In subsequent financings, which will include an IPO, we plan to raise an additional capital to commercialize Zindol® for CINV and develop other indications.

We are a European oncology start-up developing an entirely novel platform of small molecule drugs to cure currently untreatable cancers.We wholly own a pipeline of molecules that are active via novel mechanisms in cancer and several other therapeutic areas.
The mechanism of action of our lead drug, Ag5, targets cancer cells generating high levels of Reactive Oxygen Species (ROS). High ROS tumours are, in general, untreatable. This group of cancers includes KRAS-mutation driven cancers, which comprise around 30% of all cancer cases, and the worst prognosis group. There is currently no treatment for KRAS mutant cancers, which lead to more than 1 million deaths worldwide every year.
Glioblastoma Multiforme (GBM), the commonest primary brain cancer, is also a high-ROS cancer, despite the absence of mutated KRAS. There have been no new treatment options in GBM for 20 years, and prognosis is poor-averaging 18 months.
We have a follow-on compound and a pipeline of innovative molecules addressing both cancer and non-cancerous conditions.
We are raising a series A round which will allow us to gain clinical proof of concept.

Articulate Labs builds wearable medical devices amplify muscle growth throughout everyday activity to help others conquer functional limitations and to restore physical capability

Astrom Research International is a CRO consultancy focusing on Life Science between China and Europe.